↓ Skip to main content

Polypharmacy Cut-Off for Gait and Cognitive Impairments

Overview of attention for article published in Frontiers in Pharmacology, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
5 news outlets
twitter
2 X users

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
85 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Polypharmacy Cut-Off for Gait and Cognitive Impairments
Published in
Frontiers in Pharmacology, August 2016
DOI 10.3389/fphar.2016.00296
Pubmed ID
Authors

Antoine Langeard, Kristell Pothier, Remy Morello, Véronique Lelong-Boulouard, Pascale Lescure, Marie-Laure Bocca, Christian Marcelli, Pablo Descatoire, Chantal Chavoix

Abstract

Background: Polypharmacy is a well-established risk factor for falls, and these are one of the major health problems that affect the quality of life as people age. However, the risk of mobility and cognitive impairments consecutive to polypharmacy has been little addressed, despite the association between these adverse outcomes and falls. Moreover, the rare polypharmacy cut-offs were all but one arbitrarily determined. Objective: Studying relationships between polypharmacy and both mobility and cognitive impairments, and statistically determining a cut-off point in the number of medicinal molecule beyond which polypharmacy has deleterious consequences with respect to mobility and cognitive impairment. Methods: We enrolled 113 community-dwelling adults aged 55 years and older with a fall history, with or without injury, in the previous year. We carefully collected information about daily medicinal molecules taken. We assessed basic mobility and global cognition with the Time-Up-and-Go and the Montreal Cognitive Assessment (MoCA) test, respectively (clinicaltrials.gov NCT02292316). Results: Timed-Up and Go test and MoCA scores were both significantly correlated with the number of molecule, used. Receiver Operating Characteristic curves indicate, with high prediction (p < 0.002), that daily consumption of five or more molecules is associated with risk for both impaired mobility and global cognition. These relationships were independent of the number of comorbidities and of the pharmacological class. Conclusion: Community-dwelling adults aged 55 years and older who take five or more daily medicinal molecules are at high risk for both mobility and cognitive impairments. Physicians and patients should be aware of these new findings, especially when there are multiple prescribers involved in the care of the patient.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
Unknown 83 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 15%
Student > Bachelor 13 15%
Student > Master 12 14%
Student > Postgraduate 9 11%
Student > Doctoral Student 5 6%
Other 16 19%
Unknown 17 20%
Readers by discipline Count As %
Medicine and Dentistry 30 35%
Biochemistry, Genetics and Molecular Biology 7 8%
Pharmacology, Toxicology and Pharmaceutical Science 6 7%
Neuroscience 6 7%
Nursing and Health Professions 5 6%
Other 12 14%
Unknown 19 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 48. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2022.
All research outputs
#779,440
of 23,523,017 outputs
Outputs from Frontiers in Pharmacology
#250
of 17,107 outputs
Outputs of similar age
#15,952
of 339,564 outputs
Outputs of similar age from Frontiers in Pharmacology
#5
of 155 outputs
Altmetric has tracked 23,523,017 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,107 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,564 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.